BR112020018585A8 - Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer - Google Patents

Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer

Info

Publication number
BR112020018585A8
BR112020018585A8 BR112020018585A BR112020018585A BR112020018585A8 BR 112020018585 A8 BR112020018585 A8 BR 112020018585A8 BR 112020018585 A BR112020018585 A BR 112020018585A BR 112020018585 A BR112020018585 A BR 112020018585A BR 112020018585 A8 BR112020018585 A8 BR 112020018585A8
Authority
BR
Brazil
Prior art keywords
crms
cancer
chemoimmunotherapy
caloric restriction
enhance
Prior art date
Application number
BR112020018585A
Other languages
English (en)
Other versions
BR112020018585A2 (pt
Inventor
Kroemer Guido
Levesque Sarah
Pol Jonathan
Original Assignee
Inst Nat Sante Rech Med
Univ Paris
Univ Sorbonne
Assist Publique Hopitaux Paris Aphp
Univ Paris Saclay
Univ Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Paris, Univ Sorbonne, Assist Publique Hopitaux Paris Aphp, Univ Paris Saclay, Univ Paris Cite filed Critical Inst Nat Sante Rech Med
Publication of BR112020018585A2 publication Critical patent/BR112020018585A2/pt
Publication of BR112020018585A8 publication Critical patent/BR112020018585A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE MIMETICOS DE RESTRIÇÃO CALÓRICA PARA POTENCIALIZAR A QUIMIOIMUNOTERAPIA PARA O TRATAMENTO DE CÂNCER . Na maioria dos casos, a quimioterapia e a imunoterapia contra o câncer não produzem respostas duráveis e a regressão completa e permanente dos tumores estabelecidos é rara. Aqui, os inventores mostram que os chamados miméticos de restrição calórica (CRMs), que são compostos naturais ou sintéticos que mimetizam farmacologicamente os efeitos do jejum ou da restrição calórica, podem ser usados para aumentar a probabilidade de cura do câncer. A administração de vários CRMs quimicamente distintos (como hidroxicitrato, ácido lipoico e a espermidina poliamina natural) levou à regressão completa e à indução de respostas imunológicas de proteção anticancerígenas em modelos de camundongos. Este efeito foi alcançado quando CRMs foram combinados com quimioterapia e imunoterapia tendo como alvo as moléculas de ponto de verificação imunológico CTLA-4 e/ou PD-1. Portanto, a restrição calórica e os CRMs podem ser usados para sensibilizar os cânceres à quimioimunoterapia.
BR112020018585A 2018-03-12 2019-03-11 Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer BR112020018585A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18305257.0 2018-03-12
EP18305257 2018-03-12
EP18305359 2018-03-29
EP18305359.4 2018-03-29
PCT/EP2019/056041 WO2019175113A1 (en) 2018-03-12 2019-03-11 Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers

Publications (2)

Publication Number Publication Date
BR112020018585A2 BR112020018585A2 (pt) 2020-12-29
BR112020018585A8 true BR112020018585A8 (pt) 2022-12-06

Family

ID=66102028

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020018585A BR112020018585A8 (pt) 2018-03-12 2019-03-11 Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer

Country Status (11)

Country Link
US (1) US20210030703A1 (pt)
EP (1) EP3765085A1 (pt)
JP (1) JP2021517589A (pt)
KR (1) KR20210004966A (pt)
CN (1) CN112218658A (pt)
AU (1) AU2019236402A1 (pt)
BR (1) BR112020018585A8 (pt)
CA (1) CA3093742A1 (pt)
RU (1) RU2020133451A (pt)
SG (1) SG11202008696RA (pt)
WO (1) WO2019175113A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4059518A4 (en) * 2019-11-13 2023-11-29 Kyoto University COMBINATION THERAPY WITH PD-1 SIGNAL INHIBITOR
IT202000007153A1 (it) * 2020-04-03 2021-10-03 Ifom Fondazione St Firc Di Oncologia Molecolare Apporto calorico ridotto e immunoterapia per il trattamento del cancro
EP4349362A1 (en) * 2021-05-28 2024-04-10 Nippon Kayaku Kabushiki Kaisha Combined use of ubenimex and immune checkpoint inhibitors
WO2023288299A1 (en) * 2021-07-15 2023-01-19 Farber Partners, Llc Use of methanol and prodrugs thereof in therapy
CN115590187A (zh) * 2021-10-08 2023-01-13 南京纽邦生物科技有限公司（Cn） 通过施用二氢小檗碱模拟热量限制的生物学益处的方法和组合物
CN115721659A (zh) * 2021-12-09 2023-03-03 苏州百迈生物医药有限公司 一种表柔比星复方制剂及其制备方法和应用
EP4197525A1 (en) * 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN115531555B (zh) * 2022-08-19 2024-02-09 上海市第一人民医院 一种甘露糖修饰的纳米颗粒在制备治疗骨肉瘤药物中的应用
CN115282147A (zh) * 2022-08-31 2022-11-04 深圳市宝安区人民医院 罗拉匹坦或/和罗拉匹坦衍生物在抗结核分枝杆菌药物中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
GB9209628D0 (en) 1992-05-05 1992-06-17 Smithkline Beecham Plc Compounds
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
RS51309B (sr) 1998-12-23 2010-12-31 Pfizer Inc. Humana monoklonalna antitela za ctla-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EP1792991A1 (en) 1999-08-24 2007-06-06 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US7034121B2 (en) 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
GB0229734D0 (en) 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
US7257268B2 (en) 2003-02-28 2007-08-14 Aperio Technologies, Inc. Systems and methods for image pattern recognition
SI2439273T1 (sl) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki
CN101248089A (zh) 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
PL2134689T3 (pl) 2007-03-16 2014-10-31 Scripps Research Inst Inhibitory kinazy ognisk adhezyjnych
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
US8023714B2 (en) 2007-06-06 2011-09-20 Aperio Technologies, Inc. System and method for assessing image interpretability in anatomic pathology
WO2009101611A1 (en) 2008-02-11 2009-08-20 Curetech Ltd. Monoclonal antibodies for tumor treatment
JP2011512413A (ja) 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009261764B2 (en) 2008-06-17 2013-01-10 Astrazeneca Ab Pyridine compounds
JP2012510429A (ja) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよびその使用方法
PE20110435A1 (es) 2008-08-25 2011-07-20 Amplimmune Inc Composiciones antagonistas del pd-1
CA2737116C (en) 2008-09-16 2019-01-15 Historx, Inc. Reproducible quantification of biomarker expression
US20140155410A1 (en) 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
JO3067B1 (ar) 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
UA109108C2 (uk) 2008-12-09 2015-07-27 Дженентек, Інк. Антитіло до pd-l1 та його застосування для посилення функції t-клітин
EP2417984B1 (en) 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Method for treatment of blood tumor using anti-tim-3 antibody
US8289808B2 (en) 2009-04-16 2012-10-16 Chevron U.S.A., Inc. System and method to estimate compressional to shear velocity (VP/VS) ratio in a region remote from a borehole
US20110111435A1 (en) 2009-11-06 2011-05-12 SlidePath Limited Detecting Cell Surface Markers
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
ES2646863T3 (es) 2009-11-24 2017-12-18 Medimmune Limited Agentes de unión específica contra B7-H1
EP2581113B1 (en) 2010-06-11 2018-05-09 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody
AU2012210673B2 (en) 2011-01-25 2015-12-24 Air Products And Chemicals, Inc. Gasification reactor
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
DK2785375T3 (da) 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
ES2675022T3 (es) 2013-03-15 2018-07-05 Bristol-Myers Squibb Company Inhibidores de indolamina 2,3-dioxigenasa (IDO)
MX365218B (es) 2013-09-06 2019-05-27 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores.
CU24345B1 (es) 2013-09-06 2018-05-08 Aurigene Discovery Tech Ltd Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores
EP3052133A2 (en) * 2013-10-03 2016-08-10 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
US10532056B2 (en) * 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use

Also Published As

Publication number Publication date
WO2019175113A1 (en) 2019-09-19
EP3765085A1 (en) 2021-01-20
CN112218658A (zh) 2021-01-12
US20210030703A1 (en) 2021-02-04
BR112020018585A2 (pt) 2020-12-29
JP2021517589A (ja) 2021-07-26
SG11202008696RA (en) 2020-10-29
KR20210004966A (ko) 2021-01-13
CA3093742A1 (en) 2019-09-19
AU2019236402A1 (en) 2020-10-01
RU2020133451A (ru) 2022-04-12

Similar Documents

Publication Publication Date Title
BR112020018585A8 (pt) Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer
CY1123177T1 (el) Ρυθμιστης υποδοχεα ανδρογονου και χρησεις αυτου σε συνδυασμο με οξεικη αμπιρατερονη και πρεδνιζονη για τη θεραπεια καρκινου του προστατη
CY1121246T1 (el) Συζευγμα αντισωματος αντι-trop2-φαρμακου
CY1123369T1 (el) Συνθεσεις και μεθοδοι για τη ρυθμιση της εκφρασης της απολιποπρωτεϊνης (α)
CY1120363T1 (el) Συζευγμα αντισωματος-φαρμακου
CY1118899T1 (el) Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων
CY1124071T1 (el) Συζευγμα αντισωματος anti-her3 φapmakoy
CY1121925T1 (el) Συνδυαστικη θεραπεια με ενα ενζυμο που αποδομει την υαλουρονανη και εναν αναστολεα σημειων ανοσολογικου ελεγχου
CO2019013020A2 (es) Anticuerpo anti-cdh6 y conjugado farmaco-anticuerpo anticdh6
BR112018002033A2 (pt) ligantes covalentes em conjugados de anticorpo-fármaco e métodos para fabricação e uso dos mes-mos
BR112019022500A2 (pt) Microrganismos e métodos para produzir canabinoides e derivados canabinoides
BR112015032690A8 (pt) uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases
CL2018002787A1 (es) Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos.
BR112019000071A2 (pt) conjugados adjuvantes de anticorpo
BR112018002342A2 (pt) polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos
BR112019005305A2 (pt) compostos espirocíclicos
BR112018069483A2 (pt) pró-fármacos de medicamentos citotóxicos contendo grupos enzimaticamente cliváveis.
BR112016014952A2 (pt) Inibição direcionada de tgfbeta
BR112017005453A8 (pt) aminopiridiloxipirazol, seus usos, e composição farmacêutica.
BR112016028835A2 (pt) derivados de auristatina e conjugados dos mesmos
BR112016000489A8 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
MX366503B (es) Derivados de amatoxina.
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
BR112019024719A2 (pt) Composições e métodos para resposta imunológica antitumor aprimorada

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; UNIVERSITE DE PARIS (FR) ; SORBONNE UNIVERSITE (FR) ; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (FR) ; UNIVERSITE PARIS-SACLAY (FR)

B25D Requested change of name of applicant approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; SORBONNE UNIVERSITE (FR) ; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (FR) ; UNIVERSITE PARIS-SACLAY (FR) ; UNIVERSITE PARIS CITE (FR)